[go: up one dir, main page]

MA43717B1 - Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci - Google Patents

Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

Info

Publication number
MA43717B1
MA43717B1 MA43717A MA43717A MA43717B1 MA 43717 B1 MA43717 B1 MA 43717B1 MA 43717 A MA43717 A MA 43717A MA 43717 A MA43717 A MA 43717A MA 43717 B1 MA43717 B1 MA 43717B1
Authority
MA
Morocco
Prior art keywords
functional fragments
tnf alpha
alpha antibodies
relates
antibody molecules
Prior art date
Application number
MA43717A
Other languages
English (en)
Other versions
MA43717A (fr
Inventor
Tea Gunde
Sebastian Meyer
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA43717A publication Critical patent/MA43717A/fr
Publication of MA43717B1 publication Critical patent/MA43717B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des molécules d'anticorps et des fragments fonctionnels de celles-ci, capables de se lier au facteur de nécrose tumorale (tnfa). L'invention concerne également des procédés de production desdites molécules d'anticorps et leurs utilisations thérapeutiques.
MA43717A 2016-03-17 2017-03-16 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci MA43717B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16160907.8A EP3219726B1 (fr) 2016-03-17 2016-03-17 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
PCT/EP2017/056237 WO2017158092A1 (fr) 2016-03-17 2017-03-16 Anticorps anti-tnfα et fragments fonctionnels de ceux-ci

Publications (2)

Publication Number Publication Date
MA43717A MA43717A (fr) 2018-11-28
MA43717B1 true MA43717B1 (fr) 2023-11-30

Family

ID=55542576

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43717A MA43717B1 (fr) 2016-03-17 2017-03-16 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

Country Status (41)

Country Link
US (3) US11459383B2 (fr)
EP (3) EP3219726B1 (fr)
JP (2) JP7129398B2 (fr)
KR (2) KR102470235B1 (fr)
CN (1) CN109071650B (fr)
AR (1) AR107917A1 (fr)
AU (2) AU2017235387B2 (fr)
BR (1) BR112018016667A2 (fr)
CA (1) CA3011784C (fr)
CL (1) CL2018002649A1 (fr)
CO (1) CO2018009783A2 (fr)
CR (1) CR20180448A (fr)
CY (1) CY1123784T1 (fr)
DK (2) DK3219726T3 (fr)
EA (1) EA039760B1 (fr)
ES (3) ES2836349T3 (fr)
FI (1) FI3430043T3 (fr)
GE (2) GEAP202114876A (fr)
HR (2) HRP20231464T1 (fr)
HU (2) HUE052773T2 (fr)
IL (2) IL322669A (fr)
JO (2) JOP20170064B1 (fr)
LT (2) LT3219726T (fr)
MA (1) MA43717B1 (fr)
MD (1) MD3430043T2 (fr)
MX (1) MX2018011258A (fr)
MY (1) MY194041A (fr)
PH (1) PH12018501907A1 (fr)
PL (2) PL3219726T3 (fr)
PT (2) PT3219726T (fr)
RS (2) RS61374B1 (fr)
SA (1) SA518400027B1 (fr)
SG (1) SG11201807062RA (fr)
SI (2) SI3219726T1 (fr)
SM (2) SMT202000706T1 (fr)
TN (1) TN2018000298A1 (fr)
TW (2) TWI829444B (fr)
UA (1) UA128715C2 (fr)
UY (1) UY37157A (fr)
WO (1) WO2017158092A1 (fr)
ZA (5) ZA201805919B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
DK3219726T3 (da) * 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
DK3219727T3 (da) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
CA3011502A1 (fr) 2016-03-17 2017-09-21 Numab Innovation Ag Anticorps anti-tnf.alpha. et fragments fonctionnels de ceux-ci
ES2991804T3 (es) * 2017-09-19 2024-12-04 Tillotts Pharma Ag Variantes de anticuerpos
RS61883B1 (sr) * 2017-09-19 2021-06-30 Tillotts Pharma Ag Varijante antitela
ES2978167T3 (es) * 2017-09-19 2024-09-06 Tillotts Pharma Ag Variantes de anticuerpos
WO2020114616A1 (fr) 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
CZ292465B6 (cs) * 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP1891110A2 (fr) 2005-06-07 2008-02-27 Esbatech AG ANTICORPS STABLES ET SOLUBLES INHIBANT LE TNF-alpha
DK2307458T3 (en) 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
CA2730178A1 (fr) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Procedes et compositions favorisant l'administration de macromolecules
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
CN108314733A (zh) * 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
KR101712874B1 (ko) * 2010-09-30 2017-03-07 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (Fab) 및 용도
KR20240000622A (ko) 2013-06-26 2024-01-02 누맙 세러퓨틱스 아게 신규한 항체 기본구조
CA2924520C (fr) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Anticorps bispecifiques qui neutralisent a la fois tnf-alpha et il-6 : nouvel agent therapeutique pour traiter une maladie auto-immune
BR112016022055A2 (pt) * 2014-03-26 2017-10-24 Cell Medica Switzerland Ag elementos de ligação ao tnf alfa
DK3219727T3 (da) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
DK3219726T3 (da) * 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
CA3011502A1 (fr) 2016-03-17 2017-09-21 Numab Innovation Ag Anticorps anti-tnf.alpha. et fragments fonctionnels de ceux-ci
RS61883B1 (sr) * 2017-09-19 2021-06-30 Tillotts Pharma Ag Varijante antitela

Also Published As

Publication number Publication date
SI3430043T1 (sl) 2024-01-31
JOP20170064B1 (ar) 2021-08-17
HUE064238T2 (hu) 2024-02-28
MY194041A (en) 2022-11-09
US12043663B2 (en) 2024-07-23
KR20180120149A (ko) 2018-11-05
EP3219726B1 (fr) 2020-12-02
EP4275745A2 (fr) 2023-11-15
SG11201807062RA (en) 2018-09-27
CL2018002649A1 (es) 2018-11-09
MD3430043T2 (ro) 2024-02-29
SA518400027B1 (ar) 2022-03-06
JP2022130407A (ja) 2022-09-06
NZ745999A (en) 2024-08-30
ZA202108601B (en) 2022-03-30
EP3430043A1 (fr) 2019-01-23
IL322669A (en) 2025-10-01
US11459383B2 (en) 2022-10-04
JOP20210085A1 (ar) 2023-01-30
TWI829444B (zh) 2024-01-11
AU2017235387A1 (en) 2018-09-27
TWI784945B (zh) 2022-12-01
FI3430043T3 (fi) 2023-11-17
EP4275745A3 (fr) 2023-12-20
IL261031B2 (en) 2026-01-01
TW202311288A (zh) 2023-03-16
RS61374B1 (sr) 2021-02-26
CO2018009783A2 (es) 2018-09-28
ZA202108602B (en) 2022-03-30
CR20180448A (es) 2019-01-25
MA43717A (fr) 2018-11-28
CN109071650A (zh) 2018-12-21
CA3011784C (fr) 2024-04-23
DK3430043T3 (da) 2023-11-27
EP3219726A1 (fr) 2017-09-20
ES3043897T3 (en) 2025-11-26
PT3219726T (pt) 2020-12-15
DK3219726T3 (da) 2020-12-07
KR102470235B1 (ko) 2022-11-24
GEP20217307B (en) 2021-10-25
MX2018011258A (es) 2019-02-13
EA201891788A1 (ru) 2019-01-31
IL261031B1 (en) 2025-09-01
AU2017235387B2 (en) 2024-06-27
IL261031A (en) 2018-10-31
JP7129398B2 (ja) 2022-09-01
US20230272059A1 (en) 2023-08-31
CN109071650B (zh) 2022-05-13
RS64830B1 (sr) 2023-12-29
US12209122B2 (en) 2025-01-28
PL3430043T3 (pl) 2024-03-11
US20230279091A1 (en) 2023-09-07
UY37157A (es) 2017-10-31
AU2024219840A1 (en) 2024-10-10
KR20220158877A (ko) 2022-12-01
CA3011784A1 (fr) 2017-09-21
LT3219726T (lt) 2021-01-25
SMT202000706T1 (it) 2021-01-05
PL3219726T3 (pl) 2021-07-19
SI3219726T1 (sl) 2021-02-26
ZA201805919B (en) 2024-12-18
EP4275745B1 (fr) 2025-07-16
ZA202108600B (en) 2022-03-30
LT3430043T (lt) 2023-12-27
HUE052773T2 (hu) 2021-05-28
SMT202300429T1 (it) 2024-01-10
ES2963221T3 (es) 2024-03-26
HRP20210123T1 (hr) 2021-03-05
EP3430043B1 (fr) 2023-08-30
AR107917A1 (es) 2018-06-28
TN2018000298A1 (en) 2020-01-16
GEAP202114876A (en) 2021-05-13
HRP20231464T1 (hr) 2024-03-01
CY1123784T1 (el) 2022-05-27
JP2019512268A (ja) 2019-05-16
DK3430043T5 (da) 2024-09-23
EA039760B1 (ru) 2022-03-10
ES2836349T3 (es) 2021-06-24
WO2017158092A1 (fr) 2017-09-21
UA128715C2 (uk) 2024-10-09
PT3430043T (pt) 2023-11-23
BR112018016667A2 (pt) 2019-02-05
TW201739766A (zh) 2017-11-16
ZA202108599B (en) 2022-03-30
PH12018501907A1 (en) 2019-06-17
US20210198353A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
EA202092735A1 (ru) Антагонизирующее cd73 антитело
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2021000392A (es) Anticuerpos anti-mesotelina.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
EP4417263A3 (fr) Anticorps de liaison cd3
PH12017500890A1 (en) Antibody drug conjugates
JO3739B1 (ar) روابط ctla4
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
EA201691384A2 (ru) Конструкции варианта sirp-альфа и их применение
WO2018069871A3 (fr) Protéines de liaison anti-kras
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
ZA202008095B (en) Humanized antibodies against psma
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
MX2025003153A (es) Anticuerpos anti-ccr8
EA201892094A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3